Clinitouch-360: A digital health platform enabling robust end-to-end care of patients in Primary Care with depression and anxiety

Clinitouch-360：数字健康平台，可为初级保健中的抑郁和焦虑患者提供强大的端到端护理

• 批准号: 10098274
• 金额: $ 34.88万
• 依托单位: SPIRIT DIGITAL LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10098274
• 关键词: Clinitouch; 360; digital; health; platform

Public descriptionIn the UK \\\>10 million people aged 18+ (16.7% of the adult population) have depression (costing £70 billion/year from 91 million days of lost work, plus health and social care costs) and \\\>8 million have an anxiety disorder.Despite the prevalence of these conditions and shared treatment modalities (talking therapy, medication, self-support) patients presenting with anxiety and depression can experience significant problems with their care:* Incorrect diagnosis due to insufficient initial assessment (the prevalence of unrecognised bipolar disorder is 10% amongst patients prescribed antidepressants in primary care for depression or anxiety).* Deteriorating mental health during delays waiting for treatment initiation (talking therapy waitlists are 3-5 months; a 2022 Royal College of Psychiatrists report stated 43% of patients experience decline whilst waiting to start treatment).* Only 40% of patients receive medication reviews within time frames recommended in NICE guidelines, resulting in patients taking ineffective medications, or experiencing serious side effects.* Studies indicate that 30--60% of long-term antidepressant prescriptions are inappropriate.* 56% of people reducing antidepressants experience withdrawal symptoms. 46% of these patients describe their symptoms as severe and lasting for weeks or months. Gradual and hyperbolic tapering to medication cessation can mitigate this, but patients do not receive specialist support for this.* Clinicians frequently experience difficultly differentiating withdrawal symptoms from disease re-emergence when withdrawing antidepressants or anxiolytics.There is an unmet need for a digital tool supporting precision medicine and improved end-to-end management of these patients in primary care to achieve better outcomes.Solution: Spirit Digital has commercialised the 'Clinitouch' remote patient monitoring platform. Spirit will create a new module (Clinitouch-360) to better manage patients with anxiety and depression from their initial presentation.Clinitouch-360 will automate time-consuming elements of NICE guidance that prevent best practice being followed and deploy technological innovations that support patients across their treatment pathway.

在英国，1000万18岁以上的人（占成年人口的16.7%）患有抑郁症（每年损失9100万天的工作，加上健康和社会护理成本，造成700亿英镑的损失），800万人患有焦虑症。尽管这些情况普遍存在，治疗方式（谈话治疗、药物治疗、自我支持）也很普遍，但出现焦虑和抑郁的患者在护理方面可能会遇到重大问题：*由于初步评估不充分而诊断不正确（在抑郁症或焦虑症的初级保健中使用抗抑郁药物的患者中，未确诊的双相情感障碍患病率为10%）。*在等待开始治疗的延误期间，心理健康状况恶化（谈话治疗的等待名单为3-5个月；2022年皇家精神病学家学院的一份报告称，43%的患者在等待开始治疗期间经历了衰退）。*只有40%的患者在NICE指南推荐的时间框架内接受药物审查，导致患者服用无效药物或出现严重副作用。*研究表明，30- 60%的长期抗抑郁药处方是不适当的。* 56%减少抗抑郁药物的人出现戒断症状。46%的患者称他们的症状严重，持续数周或数月。逐渐和双曲逐渐减量到停止用药可以减轻这种情况，但患者没有得到专家的支持。*临床医生在停用抗抑郁药或抗焦虑药时，常常难以区分停药症状和疾病复发。对于支持精准医疗和改善初级保健患者端到端管理的数字工具的需求尚未得到满足，以实现更好的结果。解决方案：Spirit Digital已将“Clinitouch”远程患者监测平台商业化。Spirit将创建一个新的模块（Clinitouch-360），以便从患者最初的表现开始更好地管理焦虑和抑郁患者。Clinitouch-360将自动化NICE指南中耗时的元素，防止最佳实践被遵循，并部署技术创新，支持患者的整个治疗途径。